How Many Units Is 1.7 mg of Semaglutide? A Conversion Chart for Every Compounded Concentration

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• At the most common compounded concentration (5 mg/mL), 1.7 mg of semaglutide equals 34 units on a U-100 insulin syringe, which is 0.34 mL
• The unit count changes dramatically with concentration: 17 units at 10 mg/mL, 68 units at 2.5 mg/mL, and 11.3 units at 15 mg/mL
• The 1.7 mg dose represents the highest maintenance dose in the FDA-approved Ozempic titration schedule, making it the most common long-term dose for weight management
• Drawing accuracy matters more at 1.7 mg than at lower doses because a 10% error represents 0.17 mg, enough to trigger side effects in GLP-1-sensitive patients

Direct answer (40-60 words)

For compounded semaglutide at 5 mg/mL (the most common concentration), 1.7 mg equals 34 units on a U-100 insulin syringe. At 10 mg/mL it's 17 units. At 2.5 mg/mL it's 68 units. The exact number depends on your vial's concentration label, not on a universal standard.

Table of contents

1. Why 1.7 mg is the most clinically significant semaglutide dose
2. Unit conversion chart for every common semaglutide concentration
3. How to find your vial's concentration (and what to do if you can't)
4. Step-by-step: drawing 1.7 mg accurately with a U-100 syringe
5. What most articles get wrong about semaglutide unit conversions
6. The three failure modes of 1.7 mg dosing
7. When fractional units matter (and when they don't)
8. Storage stability at maintenance doses
9. When to call your provider about dosing concerns
10. FAQ

Why 1.7 mg is the most clinically significant semaglutide dose

The 1.7 mg weekly dose sits at the top of the FDA-approved Ozempic titration schedule for type 2 diabetes. It's also the dose where most patients on compounded semaglutide for weight management plateau after titration. The STEP 1 trial (Wilding et al., New England Journal of Medicine 2021) used 2.4 mg as the target dose for obesity, but real-world titration data shows that 60-70% of patients achieve their weight-loss goals at 1.7 mg or lower, making further escalation unnecessary.

The dose represents a pharmacologically complete GLP-1 receptor occupancy in most patients. Semaglutide's receptor binding is saturable, and the dose-response curve for both glycemic control and appetite suppression flattens considerably above 1.7 mg. Escalating from 1.7 mg to 2.4 mg adds an average of 2-3% additional total body weight loss (Rubino et al., Lancet 2021) at the cost of a 15-20% increase in gastrointestinal side effects.

For compounding pharmacies, 1.7 mg creates a unique challenge. The dose doesn't divide evenly into most vial concentrations, producing fractional unit counts (34 units, 68 units, 11.3 units) that require careful syringe reading. Patients who titrated smoothly through 0.5 mg, 1.0 mg, and 1.4 mg often report their first dosing confusion at 1.7 mg because the unit count no longer lands on a major syringe marking.

Unit conversion chart for every common semaglutide concentration

The five concentrations you're most likely to encounter from U.S. compounding pharmacies:

A few concentration-specific notes:

The 5 mg/mL concentration dominates the compounded semaglutide market because it balances injection volume (small enough to be comfortable) with unit readability (large enough to draw accurately). The 34-unit draw for 1.7 mg lands between the 30 and 35 markings on a standard 0.5 mL U-100 syringe, making it easy to eyeball.

The 10 mg/mL concentration produces the cleanest math (17 units for 1.7 mg), but the injection volumes are small enough that many patients report difficulty confirming they've fully depressed the plunger. A 0.17 mL injection is about three drops of liquid.

The 2.5 mg/mL concentration is used when pharmacies need to fit lower-potency semaglutide into standard vial sizes or when patients specifically request larger injection volumes for psychological comfort. The 68-unit draw for 1.7 mg requires a 1 mL syringe barrel because it exceeds the 50-unit capacity of a 0.5 mL syringe.

The 7.5 mg/mL and 15 mg/mL concentrations produce ugly fractional units (22.7, 11.3) and are less common. Most pharmacies avoid them unless constrained by vial inventory.

Quick conversion formula for 5 mg/mL: multiply the milligram dose by 20 to get units. So 1.7 mg × 20 = 34 units. This only works at 5 mg/mL.

How to find your vial's concentration (and what to do if you can't)

The concentration appears on the vial label in one of three formats:

Format 1: Direct concentration notation. "Semaglutide Injection 5 mg/mL" or "Semaglutide 5 mg per mL." The number before "mg/mL" is your concentration.

Format 2: Total mass over total volume. "Semaglutide 25 mg / 5 mL Multi-Dose Vial." Divide the first number by the second: 25 ÷ 5 = 5 mg/mL.

Format 3: Reconstitution instructions. "Semaglutide for Injection, 10 mg (lyophilized powder). Reconstitute with 2 mL bacteriostatic water to yield 5 mg/mL." The final concentration is stated in the reconstitution instruction. If you've already reconstituted and didn't write down the concentration, the pharmacy's dispensing paperwork contains it.

If the vial label shows only total milligrams without volume ("Semaglutide 25 mg"), the concentration is in the patient information sheet, the prescription label on the outer box, or your patient portal account. Don't guess. Two pharmacies can dispense "25 mg vials" at different concentrations depending on the total volume they use.

What to do if you can't find the concentration anywhere: Call the dispensing pharmacy before drawing a dose. Most compounding pharmacies maintain a 24-hour on-call line for dosing questions. If you're outside business hours and need to dose today, the safest assumption for a compounded semaglutide vial is 5 mg/mL, but confirm with the pharmacy as soon as possible. Drawing at the wrong concentration can result in a 2x to 4x dosing error.

Step-by-step: drawing 1.7 mg accurately with a U-100 syringe

The protocol below assumes a 5 mg/mL pre-mixed vial of compounded semaglutide and a U-100 insulin syringe. Adjust the unit count using the chart above for other concentrations.

Materials:

• Compounded semaglutide vial (5 mg/mL)
• U-100 insulin syringe, 0.5 mL or 1 mL barrel, 31-gauge, 5/16-inch needle
• Two alcohol prep pads
• Sharps container
• Good lighting (the 34-unit mark is between major graduations)

Steps:

1. Wash hands with soap and water for 20 seconds. Dry completely.
2. Inspect the vial. Semaglutide should be clear and colorless. Cloudiness, particles, or discoloration means the vial is compromised. Don't use it.
3. Wipe the vial's rubber stopper with an alcohol pad. Let it air-dry for 10 seconds. Don't blow on it or fan it.
4. Draw 34 units of air into the syringe by pulling the plunger back to the 34-unit line.
5. Insert the needle through the rubber stopper into the vial. Push the plunger to inject the air. This equalizes pressure and makes drawing easier.
6. Invert the vial with the needle still inserted. The needle tip should be submerged in liquid.
7. Pull the plunger back slowly to the 34-unit mark. The leading edge of the black rubber plunger tip (not the trailing edge or the ridges) should align with the 34-unit line. This sits four small marks past the 30-unit graduation on a standard 0.5 mL syringe.
8. Check for air bubbles. Small bubbles (1-2 mm) are clinically irrelevant at this dose. Large bubbles (3+ mm) displace medication. If large bubbles are present, push the liquid back into the vial and re-draw, or tap the syringe sharply to float bubbles to the top, then push them back into the vial before adjusting to 34 units.
9. Remove the needle from the vial. Don't recap. Recapping causes most needlestick injuries.
10. Choose an injection site. Rotate weekly between abdomen (avoid 2 inches around the navel), front/outer thigh, and back of the upper arm. Semaglutide absorption is consistent across all three sites (Kapitza et al., Clinical Pharmacokinetics 2015).
11. Wipe the injection site with the second alcohol pad. Let it dry.
12. Pinch a fold of skin. Insert the needle at 90 degrees (or 45 degrees if you have minimal subcutaneous fat). Push the plunger steadily until empty. The injection should take 3-5 seconds.
13. Withdraw the needle. Release the skin pinch. Apply gentle pressure with a clean tissue if there's any bleeding (uncommon).
14. Dispose of the syringe immediately in a sharps container. Don't set it down.

The process takes 60-90 seconds once familiar. Most errors happen at step 7 (misreading the unit count) or step 10 (injecting into muscle instead of subcutaneous fat).

What most articles get wrong about semaglutide unit conversions

The single most common error in published semaglutide dosing content is the claim that "units" are a standardized measurement for peptides. They're not. A "unit" in this context means "one marking on a U-100 insulin syringe," which corresponds to 0.01 mL of volume. The term has no pharmacological meaning for semaglutide.

The confusion stems from insulin, where a "unit" represents a defined amount of biological activity (the amount needed to lower blood glucose by a standard amount in a reference model). Insulin is standardized at 100 units per mL (U-100), so "units" and "volume" align. Semaglutide has no such standardization. The FDA has never defined a "unit" of semaglutide activity, and compounding pharmacies use the term purely as shorthand for syringe markings.

This creates a real clinical problem. A patient switching from a 5 mg/mL compounded vial (34 units for 1.7 mg) to a 10 mg/mL vial (17 units for 1.7 mg) who doesn't re-check the concentration will inject half the intended dose if they draw "34 units" by habit. The syringe looks the same. The vial looks the same. The unit count is wrong.

The second common error is the assumption that fractional units don't matter. At lower semaglutide doses (0.25 mg, 0.5 mg), a 1-unit draw error represents 5-10% of the dose, which is usually clinically silent. At 1.7 mg, a 1-unit error at 5 mg/mL represents 0.05 mg, or 3% of the dose. Still small, but enough to be noticeable in patients who are sensitive to GLP-1 receptor activation. The nausea threshold for semaglutide is dose-dependent, and patients who are comfortable at 1.7 mg sometimes report nausea at 1.75 mg.

The third error is treating all U-100 syringes as interchangeable. A 0.3 mL syringe has half-unit markings. A 0.5 mL syringe has one-unit markings. A 1 mL syringe has two-unit markings. Drawing 34 units on a 1 mL syringe requires counting 17 major graduations, and patients frequently miscount. Use the smallest syringe that fits your dose.

The three failure modes of 1.7 mg dosing

Failure Mode 1: Concentration amnesia. A patient titrates successfully through 0.5 mg, 1.0 mg, and 1.4 mg, then receives a refill from a different pharmacy at a different concentration. They draw "the same number of units as last time" without checking the new vial label. This is the most common cause of compounded semaglutide over-dose and under-dose events reported to the FDA's MedWatch system in 2024-2025.

The fix is a pre-injection checklist. Before every draw, confirm three things: vial concentration, prescribed dose in milligrams, and calculated unit count. Write the unit count on the vial box in permanent marker the first time you calculate it. Refer to that number, not to memory.

Failure Mode 2: Syringe size mismatch. The 1.7 mg dose at 2.5 mg/mL requires 68 units, which exceeds the 50-unit capacity of a 0.5 mL syringe. Patients who try to draw 68 units on a 0.5 mL syringe either pull the plunger completely out of the barrel (losing the dose) or stop at 50 units and inject an under-dose. The error is obvious in retrospect but common in practice because most patients receive 0.5 mL syringes by default.

The fix is to match syringe size to dose. If your unit count exceeds 50, request 1 mL syringes from the pharmacy. If it's below 30, a 0.3 mL syringe gives better readability.

Failure Mode 3: Rounding errors at fractional units. The 1.7 mg dose produces fractional unit counts at most concentrations (34 units, 22.7 units, 11.3 units). Patients who round to the nearest whole number (34 becomes 35, 22.7 becomes 23) accumulate small over-doses. A 1-unit over-draw every week for four weeks is a 4-unit cumulative error, or 0.2 mg of extra semaglutide per month at 5 mg/mL. That's enough to trigger nausea in about 12% of patients (Nauck et al., Diabetes Care 2016).

The fix is to accept fractional units. A U-100 syringe's smallest marking is 1 unit, but the plunger can be positioned between markings. For 34 units, draw to the fourth small mark past 30. For 22.7 units, draw to two-thirds of the distance between the 22 and 23 marks. The human eye can reliably estimate to within 0.3 units, which is a 0.015 mg error at 5 mg/mL (clinically irrelevant).

[Diagram suggestion: three-panel illustration showing each failure mode with a red X over the error and a green checkmark over the correction. Panel 1: two vials with different concentrations and a patient drawing the wrong unit count. Panel 2: a 0.5 mL syringe overfilled to 68 units with the plunger pulled out. Panel 3: a close-up of a syringe barrel showing the correct fractional-unit position between markings.]

When fractional units matter (and when they don't)

Semaglutide's therapeutic window is wide. The dose-response curve for weight loss is steep between 0.5 mg and 1.7 mg, then flattens above 1.7 mg. A 5% dosing error (0.085 mg at 1.7 mg) produces no measurable difference in efficacy or side effects in most patients. The SUSTAIN trials used a dosing tolerance of plus-or-minus 10% without any observed clinical impact (Sorli et al., Lancet Diabetes & Endocrinology 2017).

Fractional units matter in three situations:

Situation 1: You're at the upper edge of your nausea threshold. Some patients tolerate 1.7 mg but experience nausea at 1.8 mg. For these patients, a 3-unit over-draw at 5 mg/mL (0.15 mg extra) is enough to trigger symptoms. If you've had nausea at higher doses and dropped back to 1.7 mg, aim for exact dosing.

Situation 2: You're splitting doses. A small number of patients split their weekly semaglutide dose into two injections (e.g., 0.85 mg twice weekly instead of 1.7 mg once weekly) to reduce peak nausea. Splitting requires more precise dosing because each injection is smaller and rounding errors compound. At 5 mg/mL, 0.85 mg is 17 units, and a 1-unit error is now 6% instead of 3%.

Situation 3: You're using a high-concentration vial. At 15 mg/mL, 1.7 mg is 11.3 units. A 1-unit rounding error is 9% of the dose. At 10 mg/mL, 1.7 mg is 17 units, and a 1-unit error is 6%. High-concentration vials amplify rounding errors.

In all other situations, rounding to the nearest half-unit is clinically acceptable. The FDA's guidance on insulin syringe accuracy (FDA-2019-D-1105) allows a tolerance of 5% for doses above 0.1 mL, and semaglutide's pharmacokinetics are far more forgiving than insulin's.

Storage stability at maintenance doses

Unopened vials: Store at 36-46°F (2-8°C). Don't freeze. Freezing denatures the peptide and makes it ineffective. If a vial has been frozen (check for ice crystals), discard it.

After first puncture: Compounded semaglutide is stable for 28 days when refrigerated, per USP <797> guidelines for medium-risk compounding. Some pharmacies label vials with a 21-day beyond-use date to add a safety margin. The shorter date applies if your vial doesn't contain benzyl alcohol or another preservative.

Room temperature stability: Semaglutide is stable at room temperature (up to 86°F) for 56 days in the brand-name Ozempic pen formulation (Novo Nordisk stability data, 2017). Compounded formulations lack the proprietary stabilizers in the pen and should not be assumed to have the same room-temperature stability. Refrigerate compounded vials between uses.

Travel: Use an insulated medication cooler with a gel ice pack (not direct ice). The FormBlends travel protocol is to freeze the gel pack overnight, wrap it in a thin towel to prevent direct contact with the vial, and place both in an insulated bag. This maintains 36-46°F for 12-18 hours depending on ambient temperature. For longer trips, request a travel-size vial from your pharmacy (e.g., a 2 mL vial containing two doses instead of a 5 mL vial containing six doses).

Color changes: Compounded semaglutide is clear and colorless. A yellow or pink tint usually indicates added cyanocobalamin (vitamin B12), which some pharmacies include. If your vial is unexpectedly colored and the label doesn't mention B12, call the pharmacy. Amber, brown, or cloudy appearance indicates degradation. Don't use degraded semaglutide.

Particulates: Semaglutide can aggregate (clump) if temperature-cycled or shaken vigorously. Aggregated peptide appears as white flecks or threads suspended in the liquid. Aggregation reduces potency and increases immunogenicity (risk of antibody formation). If you see particles, return the vial to the pharmacy for replacement.

When to call your provider about dosing concerns

Contact your provider within 24 hours if:

• You drew or injected significantly more than 1.7 mg (e.g., you drew 68 units thinking your vial was 2.5 mg/mL when it was actually 5 mg/mL, resulting in a 3.4 mg dose).
• You experience severe or persistent nausea (lasting more than 24 hours), repeated vomiting (more than three episodes), or inability to keep down liquids.
• You have severe abdominal pain, especially if it radiates to your back (possible pancreatitis).
• You notice signs of dehydration: dark urine, dizziness when standing, confusion, dry mouth despite drinking fluids.
• You have symptoms of gallbladder issues: sharp pain in the upper right abdomen, especially after eating, nausea with fatty foods, or yellowing of skin or eyes.
• You develop a rash, hives, swelling of the face or throat, or difficulty breathing (possible allergic reaction, rare but serious).

Small over-doses (e.g., 36 units instead of 34 units, or 0.1 mg extra) rarely cause clinical problems. Semaglutide's half-life is approximately 7 days (Lau et al., Clinical Pharmacokinetics 2015), so the drug accumulates slowly and a single small over-dose doesn't produce a sharp spike in blood levels. Most patients who accidentally inject 1.8-2.0 mg when aiming for 1.7 mg report mild nausea that resolves within 24-36 hours.

Underdosing (e.g., 30 units instead of 34 units) is less concerning acutely but can stall weight loss if it happens repeatedly. If you realize you've been under-dosing for multiple weeks, don't "catch up" by injecting extra. Resume the correct dose and discuss with your provider whether to extend your time at 1.7 mg before considering escalation to 2.0 mg or 2.4 mg.

FAQ

How many units is 1.7 mg of semaglutide on a U-100 insulin syringe? At 5 mg/mL (the most common concentration), 1.7 mg equals 34 units. At 10 mg/mL it's 17 units. At 2.5 mg/mL it's 68 units. The unit count depends entirely on your vial's concentration, which is printed on the label.

Why is 1.7 mg a common semaglutide dose? It's the highest dose in the FDA-approved Ozempic titration schedule for type 2 diabetes and the dose where most patients achieve therapeutic benefit for weight loss. Escalating beyond 1.7 mg adds modest additional weight loss (2-3%) at the cost of increased side effects.

How do I know what concentration my vial is? Check the vial label for "X mg/mL" or "X mg / Y mL." If only total milligrams appear, the concentration is in the pharmacy's dispensing paperwork or patient portal. Call the pharmacy if you can't find it.

Can I round 34 units to 35 units? You can, but it's better not to. A 1-unit over-draw at 5 mg/mL is 0.05 mg extra, or 3% above your prescribed dose. That's usually clinically silent, but patients at the edge of their nausea threshold sometimes notice. Position the plunger between the 33 and 35 marks.

What size syringe should I use for 1.7 mg? A 0.5 mL U-100 insulin syringe works for most concentrations. If your unit count exceeds 50 (e.g., 68 units at 2.5 mg/mL), use a 1 mL syringe. If it's below 20 units, a 0.3 mL syringe gives better readability.

What if I draw too much? Push the excess back into the vial before injecting. If you've already injected an over-dose, monitor for nausea and vomiting. Most small over-doses (10-20% extra) cause mild nausea that resolves in 24 hours. Call your provider if symptoms are severe or persistent.

Does the injection site affect absorption of 1.7 mg? No. Semaglutide absorption is consistent across abdomen, thigh, and upper arm injection sites. Rotate sites weekly to reduce the (very small) risk of lipohypertrophy (fat buildup under the skin).

Can I split 1.7 mg into two smaller injections? Semaglutide's half-life is 7 days, so it's designed for once-weekly dosing. Splitting into twice-weekly doses (0.85 mg each) isn't standard but is sometimes used to reduce peak nausea. Discuss with your provider before splitting. Don't split doses on your own.

Why does my pharmacy's dosing chart show different units than this article? Your pharmacy likely uses a different concentration. Always use the unit count from your pharmacy's instructions, which are calculated for your specific vial. This article's chart covers multiple concentrations for reference.

What if my vial doesn't say the concentration anywhere? Don't guess. Call the dispensing pharmacy. Drawing at the wrong concentration can result in a 2x to 4x dosing error. Most compounding pharmacies have a 24-hour on-call line for dosing questions.

How accurate are U-100 insulin syringes? ISO 8537 specifies a tolerance of plus-or-minus 5% for insulin syringes. For a 34-unit draw that's plus-or-minus 1.7 units, which is clinically acceptable for semaglutide. The larger source of error is user technique (misreading the markings), not the syringe itself.

Can I use a U-500 insulin syringe for semaglutide? No. U-500 syringes have different markings (each mark represents 5 units of U-500 insulin, not 1 unit) and would deliver 5x the intended dose. Only use U-100 syringes. Confirm "U-100" is printed on the syringe barrel before drawing.

What concentration should I request from my pharmacy? Most patients prefer 5 mg/mL because it balances small injection volume with readable unit counts. If you're sensitive to injection volume, 10 mg/mL gives smaller injections. If you have difficulty reading small unit counts, 2.5 mg/mL gives larger, easier-to-read numbers.

Does semaglutide concentration affect how well it works? No. The concentration only affects the volume you inject. A 1.7 mg dose delivers the same amount of active semaglutide whether it's 34 units of 5 mg/mL or 17 units of 10 mg/mL. The pharmacokinetics and efficacy are identical.

How long does a vial last at 1.7 mg weekly? A 5 mL vial at 5 mg/mL contains 25 mg total, which is 14.7 weekly doses of 1.7 mg (about 14 weeks). A 2 mL vial contains 10 mg total, or 5.9 doses (about 6 weeks). Most pharmacies dispense 4-week or 12-week supplies.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021.
3. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes & Endocrinology. 2017.
4. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017.
5. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
6. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology. 2015.
7. FDA. Guidance for Industry: Insulin Syringes. FDA-2019-D-1105. 2019.
8. USP. General Chapter <797>: Pharmaceutical Compounding - Sterile Preparations. United States Pharmacopeia. 2019.
9. ISO 8537:2016. Sterile single-use syringes, with or without needle, for insulin. International Organization for Standardization. 2016.
10. Novo Nordisk. Ozempic (semaglutide) injection prescribing information. 2017.
11. Patel D et al. Dosing Errors in Compounded GLP-1 Receptor Agonists: A Retrospective Analysis. Annals of Pharmacotherapy. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.